FR2624742A1 - Procede de preparation de lymphocytes a activite lak - Google Patents

Procede de preparation de lymphocytes a activite lak Download PDF

Info

Publication number
FR2624742A1
FR2624742A1 FR8816751A FR8816751A FR2624742A1 FR 2624742 A1 FR2624742 A1 FR 2624742A1 FR 8816751 A FR8816751 A FR 8816751A FR 8816751 A FR8816751 A FR 8816751A FR 2624742 A1 FR2624742 A1 FR 2624742A1
Authority
FR
France
Prior art keywords
lymphocytes
process according
cells
lak
plastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8816751A
Other languages
English (en)
French (fr)
Other versions
FR2624742B1 (enExample
Inventor
John Chatfield Hiserodt
Nikola Vujanovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of FR2624742A1 publication Critical patent/FR2624742A1/fr
Application granted granted Critical
Publication of FR2624742B1 publication Critical patent/FR2624742B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR8816751A 1987-12-18 1988-12-19 Procede de preparation de lymphocytes a activite lak Granted FR2624742A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/134,717 US5057423A (en) 1987-12-18 1987-12-18 Method for the preparation of pure LAK-active lymphocytes

Publications (2)

Publication Number Publication Date
FR2624742A1 true FR2624742A1 (fr) 1989-06-23
FR2624742B1 FR2624742B1 (enExample) 1993-02-26

Family

ID=22464654

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8816751A Granted FR2624742A1 (fr) 1987-12-18 1988-12-19 Procede de preparation de lymphocytes a activite lak

Country Status (3)

Country Link
US (1) US5057423A (enExample)
JP (1) JPH02109976A (enExample)
FR (1) FR2624742A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657783A1 (fr) * 1990-02-07 1991-08-09 Fondation Nale Transfusion San Procede de preparation de derives sanguins et derives obtenus par ce procede.

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63239103A (ja) * 1987-03-27 1988-10-05 Ulvac Corp 立方晶窒化硼素被覆体およびその製造法
EP0726772B1 (en) * 1993-08-09 2001-11-07 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
EP0815204B1 (en) * 1995-03-17 2006-09-06 The Regents Of The University Of California Method for treating tumors by alloactivated human donor lymphocytes
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6316257B1 (en) 1996-03-04 2001-11-13 Targeted Genetics Corporation Modified rapid expansion methods (“modified-REM”) for in vitro propagation of T lymphocytes
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
EP1390076A4 (en) * 2001-04-27 2004-12-15 Xcyte Therapies Inc Maturation of antigen-presenting cells with activated cells
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
CN1520312A (zh) * 2001-06-01 2004-08-11 �Ƹ��� T细胞诱导的组织修复和再生
TWI311586B (en) 2001-08-15 2009-07-01 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic t lumphocytes
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
EP2034009B1 (en) 2002-02-08 2014-01-15 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
AU2003253684A1 (en) 2002-06-28 2004-01-19 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DE10319430B4 (de) * 2003-04-29 2009-01-15 Max Hauser Süddeutsche Chirurgiemechanik GmbH Vorrichtung zum Spreizen von Gewebe
US20040224402A1 (en) * 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
CN1898569A (zh) * 2003-10-24 2007-01-17 伊缪因艾德有限公司 治疗方法
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
DK3234107T3 (da) 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
WO2017182608A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions for the treatment of b-cell malignancies
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
US20250152714A1 (en) 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247613A2 (en) * 1986-05-30 1987-12-02 Terumo Kabushiki Kaisha Improved process for preparing lymphokine activated killer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247613A2 (en) * 1986-05-30 1987-12-02 Terumo Kabushiki Kaisha Improved process for preparing lymphokine activated killer cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEDERATION PROCEEDINGS, vol. 46, no. 4, 5 mars 1987, page 1500, résumé no. 6906, Federation of American Societies for Experimental Biology; N.L. VUJANOVIC et al.: "Lymphokine activated killer cells in rats: analysis of precursor and effector cell phenotypes and relationship to large granular lymphocytes" *
FEDERATION PROCEEDINGS, vol. 46, no. 4, 5 mars 1987, page 1500, résumé no. 6907, Federation of American Societies of Experimental Biology; J.C. HISERODT et al.: "Lymphokine activated killer cells in rats: use as a novel method for cleansing bone marrow of residual tumor for autotransplantation" *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 316, no. 15, 9 avril 1987, pages 889-897, Massachusetts Medical Society; S.A. ROSENBERG et al.: "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657783A1 (fr) * 1990-02-07 1991-08-09 Fondation Nale Transfusion San Procede de preparation de derives sanguins et derives obtenus par ce procede.
WO1991012316A1 (fr) * 1990-02-07 1991-08-22 Fondation Nationale De Transfusion Sanguine Procede de preparation de derives sanguins et derives obtenus par ce procede

Also Published As

Publication number Publication date
FR2624742B1 (enExample) 1993-02-26
JPH02109976A (ja) 1990-04-23
US5057423A (en) 1991-10-15

Similar Documents

Publication Publication Date Title
FR2624742A1 (fr) Procede de preparation de lymphocytes a activite lak
Deloach et al. A dialysis procedure for loading erythrocytes with enzymes and lipids
King et al. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules
Suda et al. Participation of oxidative stress in the process of osteoclast differentiation
JPH0534946B2 (enExample)
KR20210041578A (ko) 치수 유래 세포의 제조 방법
FR2466990A1 (fr) Compositions synergiques pour stimuler l'activite phagocytaire, comprenant une solution contenant de la muramidase et un sel de l'acide hyaluronique
Andreesen et al. Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation
Josefsen et al. Fluorescence-activated cell sorted rat islet cells and studies of the insulin secretory process
Toftdal et al. Oxygen releasing hydrogels for beta cell assisted therapy
US4699912A (en) Use of Lycorine as an immunosuppressor
Lee et al. Transplantation of human corneal limbal epithelial cell sheet harvested on synthesized carboxymethyl cellulose and dopamine in a limbal stem cell deficiency
Pilwat et al. Immobilization of human red blood cells
EP2376069B1 (en) Microparticles comprising adipose stem cells
Capo et al. Non-specific binding by macrophages: evaluation of the influence of medium-range electrostatic repulsion and short-range hydrophobic interaction
Bernanke et al. Hyaluronate binding and degradation by cultured embryonic chick cardiac cushion and myocardial cells
EP4095237A1 (en) Method for producing three-dimensional cell structure
Friedman et al. Lipoprotein lipase activity in cultured mesenchymal rat heart cells Part 5. effect on enzyme activity of the glycosylation inhibitors, 2-deoxyglucose and tunicamycin
Fridkis-Hareli et al. Patterns of dual lymphocyte development in co-cultures of foetal thymus and lymphohaemopoietic cells from young and old mice
Musgrave et al. Sexual agglutination in Chlamydomonas eugametos before and after cell fusion
Hubbard et al. Spontaneous transmitter release and ACh sensitivity during glutaraldehyde fixation of rat diaphragm
Tuch et al. Typing of human fetal organs for the histocompatibility antigens A, B and DR
JPH07196508A (ja) 移植片対宿主疾患の治療のための医薬組成物
Ikehara Intractable diseases and bone marrow transplantation
Polgar et al. Reversal of PHA-induced blastogenesis in human lymphocyte cultures

Legal Events

Date Code Title Description
ST Notification of lapse